- Home
- Publications
- Publication Search
- Publication Details
Title
Checkpoint inhibitors in Hodgkin's lymphoma
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 96, Issue 4, Pages 335-343
Publisher
Wiley
Online
2015-11-12
DOI
10.1111/ejh.12697
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The new therapeutical scenario of Hodgkin lymphoma
- (2015) A. Stathis et al. ANNALS OF ONCOLOGY
- Immune checkpoint blockade in hematologic malignancies
- (2015) P. Armand BLOOD
- Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy
- (2015) Locke J. Bryan et al. BLOOD REVIEWS
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
- (2014) M A Kharfan-Dabaja et al. BONE MARROW TRANSPLANTATION
- Novel immunotherapies for hematologic malignancies
- (2014) Michelle H. Nelson et al. IMMUNOLOGICAL REVIEWS
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality
- (2013) A. Saha et al. BLOOD
- Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion
- (2013) P. Bachireddy et al. BLOOD
- New drugs and targeted treatments in Hodgkin’s lymphoma
- (2013) Mariano Provencio et al. CANCER TREATMENT REVIEWS
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- XVII. Radiotherapy in early stage Hodgkin lymphoma
- (2013) Tim Illidge HEMATOLOGICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome
- (2012) Yago Nieto et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
- (2012) A. Younes et al. BLOOD
- Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
- (2012) Y. L. Kasamon et al. BLOOD
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
- (2012) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
- (2012) Leo I. Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
- (2012) Andreas Engert et al. LANCET
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family
- (2011) Hélène Bour-Jordan et al. IMMUNOLOGICAL REVIEWS
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma
- (2010) N. Puig et al. HAEMATOLOGICA
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Putting the brakes on BTLA in T cell–mediated cancer immunotherapy
- (2010) Chrystal M. Paulos et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
- (2010) Donatella Aldinucci et al. JOURNAL OF PATHOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
- (2010) Jeffrey Weber SEMINARS IN ONCOLOGY
- The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation
- (2009) Guifang Cai et al. IMMUNOLOGICAL REVIEWS
- Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+
- (2009) Karen S. Sfanos et al. PROSTATE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation
- (2008) K J Thomson et al. BONE MARROW TRANSPLANTATION
- Managing relapsed and refractory Hodgkin lymphoma
- (2008) Pauline Brice BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started